Interaction of nicotine and prostaglandins in the cardiovascular system.
D015121:6-Ketoprostaglandin F1 alpha; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001792:Blood Platelets / Q000201:enzymology; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D006801:Humans; D006940:Hyperemia / Q000503:physiopathology; D007213:Indomethacin / Q000494:pharmacology; D007668:Kidney / Q000201:enzymology; D008861:Microsomes / Q000201:enzymology; D009131:Muscle, Smooth, Vascular / Q000378:metabolism; D009538:Nicotine / Q000494:pharmacology*; D011247:Pregnancy; D011453:Prostaglandins / Q000502:physiology*; D011458:Prostaglandins E / Q000096:biosynthesis; D012907:Smoking; D014469:Umbilical Arteries / Q000378:metabolism
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D011458:Prostaglandins E; D016718:Arachidonic Acid; D015121:6-Ketoprostaglandin F1 alpha; D009538:Nicotine; D011464:Epoprostenol; D015232:Dinoprostone; D007213:Indomethacin